Abstract: The invention relates to antibodies to T cells as therapeutics. The object underlying the invention is to provide antibodies for a clinical therapy for prolonging the immunosuppressive antibody effect while avoiding the formation of antiantibodies. This object is achieved by providing antibodies consisting of at least two different groups which are applied at different times and in which at least one antibody of group B differs from one antibody of group A in the constant regions of its heavy chains and wherein group A, which is first applied once or several times, has a T-cell eliminating effect, while the other group B (which is applied at a different time) has a T-cell eliminating and/or T-cell antigen modulating effect.

Abstract: The invention relates to a material dispenser. For particularly efficient packaging, the invention proposes a material dispenser (1) having a first roller (2) for a web material, in particular for a web-like packaging material, and having at least one second roller (3, 6) for a binding material, in particular for a string-like, strip-like or ribbon-like binding material, the rollers being connected to one another by at least one connecting element (7, 15).

Abstract: According to the invention, a method is provided wherein intact bispecific or trispecific antibodies which at the same time bind to the T cell receptor complex of a T cell, to tumor-associated antigens on a tumor cell, and, via the Fc portion of the bispecific antibody, to Fc receptor-positive cells are used for the induction of an anti-tumour immunity in humans and animals.

Abstract: According to the invention, a method is provided wherein intact bispecific or trispecific antibodies which at the same time bind to the T cell receptor complex of a T cell, to tumour-associated antigens on a tumour cell, and, via the Fc portion of the bispecific antibody, to Fc receptor-positive cells are used for the induction of an anti-tumour immunity in humans and animals.

Abstract: The invention concerns medicaments containing antibodies which have at least one specificity and detect the MHCII antigen of a patient to be treated. The invention further concerns antibodies with two or more specificities which detect the MHCII antigen of a patient, and diagnostic compositions containing these antibodies.

Abstract: A pharmaceutical kit and process useful for achieving prolonged immunosuppression and tumor cell elimination, wherein the kit comprises a first antibody having binding specificity for T cells and is capable of eliminating T cells in vivo; and a second antibody, having binding specificity for T cells and is capable of eliminating T cells in vivo, capable of modulating the antigen effect of T cells or both, wherein said first antibody differs from said second antibody in the constant region of its heavy chains and thus belongs to a different animal species, wherein said first antibody and said second antibody are maintained separately in said kit, and wherein in said process said first antibody is first applied once or several times and said second antibody is applied at a different time from said first antibody.

Abstract: The present invention discloses a procedure for the destruction of contaminating tumor cells in stem cell transplants ex vivo using intact bispecific antibodies.

Abstract: A hybrid fusion cell comprising:a) a malignant B cell which expresses an idiotypic antibody; andb) a hybridoma which expresses an antibody which is capable of being internalized on a professional antigen presenting cell.

Abstract: The present invention discloses a procedure for the destruction of contaminating tumor cells in stem cell transplants ex vivo using intact bispecific antibodies.

Abstract: A pharmaceutical kit and process useful for achieving prolonged immunosuppression and tumor cell elimination, wherein the kit comprises a first antibody having binding specificity for T cells and is capable of eliminating T cells in vivo; and a second antibody, having binding specificity for T cells and is capable of eliminating T cells in vivo, capable of modulating the antigen effect of T cells or both, wherein said first antibody differs from said second antibody in the constant region of its heavy chains and thus belongs to a different animal species, wherein said first antibody and said second antibody are maintained separately in said kit, and wherein in said process said first antibody is first applied once or several times and said second antibody is applied at a different time from said first antibody.